girentuximab

You have access
DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of ¹⁷⁷Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma
Cameron N. Johnstone, Laura D. Osellame, Zhipeng Cao, Alexander F. McDonald, Angela Rigopoulos, Ingrid J.G. Burvenich, Christian W. Wichmann, Nancy Guo, Alesia N. Ivashkevich, Michael P. Wheatcroft, Edwin B. Yan, Astrid Zimmermann, Frank T. Zenke, Christian Sirrenberg, Fiona E. Scott and Andrew M. Scott

Journal of Nuclear Medicine March 1, 2025, 66 (3) 385-390; DOI: https://doi.org/10.2967/jnumed.124.268695
You have access
Optical Imaging of Renal Cell Carcinoma with Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab
Constantijn H.J. Muselaers, Alexander B. Stillebroer, Mark Rijpkema, Gerben M. Franssen, Egbert Oosterwijk, Peter F.A. Mulders, Wim J.G. Oyen and Otto C. Boerman

Journal of Nuclear Medicine June 1, 2014, 55 (6) 1035-1040; DOI: https://doi.org/10.2967/jnumed.114.137356
You have access
Tyrosine Kinase Inhibitor Sorafenib Decreases ¹¹¹In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
Constantijn H.J. Muselaers, Alexander B. Stillebroer, Ingrid M.E. Desar, Marye J. Boers-Sonderen, Carla M.L. van Herpen, Mirjam C.A. de Weijert, Johan F. Langenhuijsen, Egbert Oosterwijk, William P.J. Leenders, Otto C. Boerman, Peter F.A. Mulders and Wim J.G. Oyen

Journal of Nuclear Medicine February 1, 2014, 55 (2) 242-247; DOI: https://doi.org/10.2967/jnumed.113.131110

Main menu